On the morning of September 24, 2024, Henan EMICRO Biomedicine Co., Ltd. achieved an important milestone - the Phase I clinical trial of the innovative anti-tumor drug TM471-1 capsule was launched.

  The kickoff meeting was conducted through online video connection between EMICRO Biomedicine and Peking University Cancer Hospital, Boji Pharmaceutical and other units. Professor Zhu Jun, a renowned expert in the field of blood tumor treatment in China, and the Secretary and Dean of the Party Committee of Peking University Cancer Hospital, as well as Professor Song Yuqin, Vice Dean and Deputy Director of the Lymphoma Department of Peking University Cancer Hospital, and members of the experimental medical team, attended the launch meeting on behalf of the clinical trial undertaker. Dr. Yang Yinke, Chief Scientist of EMICRO Biomedicine, General Manager Li Wei, Deputy General Manager Jin Jianxin, Medical Director Dr. Yu Lifang, and Director of the Analytical Laboratory Li Honglei attended the launch ceremony on behalf of the applicant.

  Peking University Cancer Hospital is the research institution (and also the leading unit) for this clinical trial, with the leading department being the Department of Lymphatic Oncology. At the launch ceremony, at the request of the applicant, the experimental team announced the entire trial process of a phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of BTK inhibitor TM471-1 capsule in B-cell non Hodgkin lymphoma (NHL) patients through online PPT, demonstrating the scientific, standardized, and impartial conditions for the trial. Professor Zhu Jun from the applicant and Dr. Yang Yinke from the commissioning party respectively delivered speeches, wishing the experiment a complete success.